Unique Alzheimer's Disease Paired Helical Filament Specific Epitopes Involve Double Phosphorylation at Specific Sites
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) paired helical filaments (PHFs), building blocks of neurofibrillary tangles (NFTs) are composed of hyperphosphorylated forms of the microtubule-associated protein tau (i.e., PHF-tau). Currently, much effort is devoted to the development of diagnostic antibodies specific for PHF-tau since elevated tau levels are found in the cerebral spinal fluid of AD patients. To this end, we have mapped the epitopes of a large panel of monoclonal antibodies (mAbs) that recognized only phosphorylation dependent epitopes on PHF-tau. These mAbs include the PHF-tau specific mAb AT10 and 12 newly developed anti-PHF mAbs that recognize PHF-tau but not autopsy-derived normal adult tau on Western-blot and enzyme-linked immunosorbent assay (ELISA). Epitope analysis, together with data on known binding sites of previously published mAbs, revealed that Ser214, Thr231, and Ser396 are immunodominant phosphorylated amino acids in PHF-tau. Six of the 12 new mAbs recognized one of these three phosphorylated sites. With the exception of AT10 and PHF-27, all the mAbs also labeled fetal tau and biopsy-derived tau. Since mAbs AT10 and PHF-27 had little or no affinity for fetal tau and biopsy tau, they can be considered as the first "true" PHF-specific antibodies capable of distinguishing tau isoforms from normal versus AD subjects, suggesting a possible utility of these mAbs as diagnostic markers. Remarkably, the true PHF-specific antibodies recognized peptide sequences phosphorylated on more than one amino acid residue. The peptide recognition of mAb AT10 required the simultaneous phosphorylation of Thr212 and Ser214, and the peptide recognition of mAb PHF-27 was markedly increased when both the primary site Thr231 and the subsite Ser235 were phosphorylated. Since AT10 and PHF-27 are the only mAbs currently available that bind specifically to PHF-tau, these data suggest that double phosphorylation at Thr212/Ser214 and Thr231/Ser235 may be unique to PHF-tau. These data may facilitate the development of mAbs that can be used as specific diagnostic reagents for the detection of altered tau in cerebrospinal fluid of AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Biernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643
Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer‐like state.
Drewes, G., Lichtenberg‐Kraag, B., Döring, F., Mandelkow, E. M., Biernat, J., Goris, J., Dorée, M., & Mandelkow, E. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05272.x · Cited by 565
Proline-directed and non-proline-directed phosphorylation of PHF-tau
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., & Ihara, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.823 · Cited by 557
Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41890-x · Cited by 430
Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., & Cras, P. (1994) · Biochemical Journal · doi:10.1042/bj3010871 · Cited by 375
The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine
Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361
Cited by
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citationBuée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,015
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
“AT100. AT100 is directed against the doubly phosphorylated epitope T212 and S214 which can be created by sequential phosphorylation with GSK-3β and PKA; it is one of the most specific antibodies against Alzheimer tau [ 29 , 57].”
BackgroundTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567
Self-citationIshihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564
Self-citationJackson, G. R., Wiedau-Pazos, M., Sang, T.-K., Wagle, N., Brown, C. A., Massachi, S., & Geschwind, D. H. (2002) · Neuron · doi:10.1016/s0896-6273(02)00706-7 · Cited by 488
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 469
Self-citationHanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455
Post-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437
Leroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
Hanger, D. P., Betts, J. C., Loviny, T. L. F., Blackstock, W. P., & Anderton, B. H. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062465.x · Cited by 377
Buée, L., & Delacourte, A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00550.x · Cited by 362
Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P., McCarthy, S., Coskran, T., Carlo, A., Seymour, P. A., Burkhardt, J. E., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040577797 · Cited by 341
Cripps, D., Thomas, S. N., Jeng, Y., Yang, F., Davies, P., & Yang, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512786200 · Cited by 312
Tau protein as a differential biomarker of tauopathies
Sergeant, N., Delacourte, A., & Buée, L. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.020 · Cited by 313
Illenberger, S., Zheng-Fischhöfer, Q., Preuss, U., Stamer, K., Baumann, K., Trinczek, B., Biernat, J., Godemann, R., Mandelkow, E.-M., & Mandelkow, E. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.6.1495 · Cited by 304
Sergeant, N., Wattez, A., & Delacourte, A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721243.x · Cited by 286
Cho, J., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02155.x · Cited by 282
“The wild-type tau was phosphorylated by GSK3b at the AT180 epitope; AT180 has been shown to recognize Thr231 when the site is phosphorylated (Hoffmann et al. 1997).”
BackgroundInfluentialAcetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Brain · doi:10.1093/brain/aws013 · Cited by 281
Self-citationJeganathan, S., Hascher, A., Chinnathambi, S., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805300200 · Cited by 278
Jicha, G. A., Lane, E., Vincent, I., Otvos, L., Hoffmann, R., & Davies, P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052087.x · Cited by 264
Self-citationMitchell, T. W., Mufson, E. J., Schneider, J. A., Cochran, E. J., Nissanov, J., Han, L., Bienias, J. L., Lee, V. M. ‐., Trojanowski, J. Q., Bennett, D. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10086 · Cited by 253
Self-citationFerrer, I., Blanco, R., Carmona, M., Ribera, R., Goutan, E., Puig, B., Rey, M. J., Cardozo, A., Viñals, F., & Ribalta, T. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00387.x · Cited by 239
Schmidt, M., Zhukareva, V., Newell, K., Lee, V., & Trojanowski, J. (2001) · Acta Neuropathologica · doi:10.1007/s004010000330 · Cited by 230
“These antibodies as well as their respective epitopes are depicted schematically in Fig. 1. The following anti-tau antibodies (with their respective dilutions shown in parentheses) were used for immunohistochemistry: antiserum T3P (1:8,000) [2], mAb PHF6 (1:5,000 [ 7 ] and antiserum N-tau (1:20,000), produced by V.M.-…”
MethodSelf-citationCharacterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration
Forman, M. S., Lal, D., Zhang, B., Dabir, D. V., Swanson, E., Lee, V. M.-Y., & Trojanowski, J. Q. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0081-05.2005 · Cited by 198
Self-citationEarly axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice
Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., & Brion, J.-P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070345 · Cited by 135
Tau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Self-citationAmniai, L., Barbier, P., Sillen, A., Wieruszeski, J.-M., Peyrot, V., Lippens, G., & Landrieu, I. (2009) · The FASEB Journal · doi:10.1096/fj.08-121590 · Cited by 105
Galas, M.-C., Dourlen, P., Bégard, S., Ando, K., Blum, D., Hamdane, M., & Buée, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601849200 · Cited by 97
The role of tau in Alzheimer's disease
Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00002-0 · Cited by 85
Self-citationHéraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J.-N., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.010 · Cited by 80
Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment
Mitchell, T. W., Nissanov, J., Han, L.-Y., Mufson, E. J., Schneider, J. A., Cochran, E. J., Bennett, D. A., Lee, V. M.-Y., Trojanowski, J. Q., & Arnold, S. E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801206 · Cited by 78
Self-citationTakahashi, M., Weidenheim, K. M., Dickson, D. W., & Ksiezak-Reding, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.33 · Cited by 56
“Analysis of tau levels, phosphorylated epitopes, and tau isoform content clarified some of the morphological and biochemical differences among tauopathies (13, 22, 23).”
BackgroundPerea, J. R., Ávila, J., & Bolós, M. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.007 · Cited by 54
Maurage, C.-A., Sergeant, N., Ruchoux, M.-M., Hauw, J.-J., & Delacourte, A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0608-7 · Cited by 51
“The phosphorylation of tau differs from AD brain tissue to normal brain sample extracts, as shown by phosphorylation-dependent antibodies [11, 25, 27 , 35].”
Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice
Schild, A., Ittner, L. M., & Götz, J. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.066 · Cited by 38
Metadata
- Authors
- Hoffmann, R., Lee, V. M.-Y., Leight, S., Varga, I., & Otvos, L.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1997-07-01
- Volume
- 36
- Issue
- 26
- Pages
- 8114-8124
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1998047781
- Cited by
- 152
- References
- 8
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.